



IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
06628	TRANSCENTA-B	2021/09/17	2021/09/28	2021/09/29

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit www.cfs.com.hk or contact our account executives or customer service officers

Subscription Details via CASH Securities

Offer Period	2021/09/14-2021/09/17
Closing Time for Margin Application	N/A
Subscription Fee	N/A
Days For Margin Financing	N/A
Indicative Interest Rate	N/A

*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

Transcenta Holding Limited (6628.HK)

Share Offer Highlights

Total Number of Offer Shares:	40,330,000 Shares (subject to the Over-allotment Option)
- Number of Public Offer Shares:	4,033,000 Shares (subject to reallocation)
- Number of Placing Shares:	36,297,000 Shares (subject to reallocation and the Over-allotment Option)
Number of Shares per Lot:	500 Shares
Offer Price:	HKD 15.80-16.00 per Share
2020 Historical P/E ratio:	-
Sponsor:	Goldman Sachs 、CICC

Company Overview

This company is a clinical stage biopharmaceutical company that integrates the capacities of discovery, research, development, manufacturing and business development. Its management team and the key operations, including clinical development, regulatory access and business development are based both in China and the United States, whereas its discovery, research and development, process development and manufacturing teams are based in China. It adopts a global approach to maximize operational efficiency. Concurrently, it leverages the efficient regulatory approval pathway to accelerate the Investigational New Drug (IND) applications and early-phase clinical trials in the United States and to advance clinical trials in the indications with significant unmet medical needs from the large patient population in China. As of the Latest Practicable Date, in relation to its key products, it owned three PCT priority applications, two pending PCT applications and two pending patent applications in Taiwan, and co-owned one PCT priority application with its collaborator, Beijing Cancer Hospital. In addition, it also in-licensed one issued Chinese patent in relation to TST002.

For the year ended December 31, 2019 and 2020, the Company's net losses were RMB 395.26 mn, and RMB 316.63 mn respectively.

Source

IPO Prospectus

Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026



Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.